Lisinopril and Gabapentin Interaction: What Patients and Clinicians Need to Know

Does a lisinopril-gabapentin interaction actually exist?

A clinically relevant interaction exists, but it is not the kind most people picture when they hear "drug interaction." Lisinopril does not inhibit or induce cytochrome P450 enzymes, and gabapentin is not metabolized in the liver at all, so there is no enzyme-based interaction to worry about. The interaction that does exist runs through the kidney: gabapentin is cleared almost entirely by renal excretion, and anything that lowers glomerular filtration rate (GFR), including the hemodynamic effect of an ACE inhibitor like lisinopril, dehydration, or added diuretics, can slow gabapentin clearance and raise circulating levels enough to increase sedation, dizziness, and fall risk.

This is the core fact-dense summary of the page: lisinopril and gabapentin have no direct pharmacokinetic interaction, but both are renally eliminated, so any reduction in kidney function shared by the two drugs' clearance pathways can raise gabapentin exposure and CNS depression risk. Most drug interaction databases (Lexicomp, Micromedex, Drugs.com) classify the pairing as minor for this reason, which reflects the absence of a direct mechanism rather than an absence of real-world consequence in patients with reduced kidney function.

How each drug is eliminated from the body

Lisinopril is an ACE inhibitor. It is excreted largely unchanged in the urine, is not significantly protein-bound, and is not a substrate, inhibitor, or inducer of P-glycoprotein or CYP450 enzymes. Renal impairment prolongs its half-life, which is why product labeling generally calls for lower starting doses as creatinine clearance declines.

Gabapentin is likewise eliminated almost entirely by renal excretion of unchanged drug, with essentially no hepatic metabolism. Its absorption also depends on a saturable intestinal transporter, so higher single doses are absorbed proportionally less well; this is an absorption-limiting effect unrelated to lisinopril. Because gabapentin clearance tracks closely with creatinine clearance, the FDA label for gabapentin includes a renal dose-adjustment table with lower total daily doses at lower creatinine clearance bands, and a specific post-dialysis dosing recommendation for patients on hemodialysis. [2] The precise numeric cutoffs and dose ranges in that table should be confirmed against the current label before use in individual dosing decisions, since labeling can be updated.

Neither drug's elimination pathway touches the other's directly. That is why the interaction is properly described as pharmacodynamic-through-renal-physiology rather than pharmacokinetic in the classic sense of one drug altering another drug's metabolism or transport.

Why lisinopril can push gabapentin levels up

The mechanism runs in three steps:

1. Lisinopril lowers intraglomerular pressure and systemic blood pressure, which can modestly reduce GFR, particularly in patients who are volume-depleted, have pre-existing chronic kidney disease (CKD), or are also taking a diuretic.
2. A reduced GFR slows gabapentin's renal clearance, which can meaningfully lengthen its half-life and raise steady-state plasma concentration.
3. Elevated gabapentin levels increase CNS depression, presenting as sedation, dizziness, unsteady gait, or cognitive slowing.

This same physiological pathway is at play with any ACE inhibitor, not something specific to lisinopril; enalapril, ramipril, and similar agents carry the same theoretical risk through the same GFR-dependent mechanism.

Patients most likely to experience this cascade in a meaningful way include those with CKD stage 3 or beyond, older adults (kidney function tends to decline with age), patients recently started on a diuretic alongside lisinopril, and anyone experiencing an acute illness with vomiting, diarrhea, or reduced oral intake that can transiently drop GFR. Chronic kidney disease is common in the U.S. adult population, and ACE inhibitors are frequently used specifically to slow CKD progression, so the overlap between CKD, ACE inhibitor use, and gabapentin use for neuropathic pain is not a rare edge case. [4]

Evidence-status assessment: what is known, plausible, or unverified

Use this table as a starting checklist: before treating any specific number in this space as fact, confirm it against the current FDA label or the original guideline document rather than a secondary summary.

Recognizing gabapentin accumulation

Watch for:

• Excessive drowsiness or difficulty staying awake during the day
• Unsteady gait or a new fall
• Slurred speech or word-finding trouble
• Confusion or noticeable cognitive slowing
• Nausea beyond what is typical for the patient's usual gabapentin tolerance

Respiratory depression is uncommon at standard gabapentin doses alone but becomes a real concern when gabapentin is combined with opioids or other CNS depressants, particularly in a patient whose renal clearance has declined. Regulatory safety communications have warned that gabapentinoids can cause serious breathing problems in combination with CNS depressants and in patients with impaired renal function; this warning is directly relevant to a patient on lisinopril, gabapentin, and an opioid together.

Does gabapentin affect lisinopril's blood-pressure-lowering effect?

Gabapentin has been reported to have mild vasodilatory effects and has been associated with orthostatic hypotension in some populations. If a patient's blood pressure is already well controlled on lisinopril, adding gabapentin could plausibly produce additive dizziness on standing. The specific magnitude of this effect in the literature varies by study population, and a precise odds ratio should not be quoted here without direct verification of the source study; the practical takeaway is unchanged either way: counsel patients on rising slowly from seated or lying positions, especially if they are older or have autonomic neuropathy from diabetes.

Gabapentin's own edema risk (reported in a meaningful minority of patients in trials) deserves separate attention, because a clinician who adds a diuretic to manage gabapentin-related edema will, in turn, reduce GFR and potentially raise gabapentin levels further, a self-reinforcing cascade worth anticipating rather than treating as a coincidence.

Monitoring protocol

Before starting the combination (whichever drug is added second):

• Serum creatinine and calculated eGFR
• Serum electrolytes, including potassium (lisinopril reduces aldosterone and can raise potassium independent of gabapentin)
• Blood pressure in both seated and standing positions
• A fall-risk assessment in patients over 65

Ongoing monitoring:

If eGFR drops into a lower band while a patient is on a stable gabapentin dose, the practical step is to review gabapentin dosing against the current FDA label before assuming any new symptom has an unrelated cause. This is a case where kidney function change should prompt a proactive dose review rather than waiting for sedation to appear.

Special populations

Diabetes. Diabetic nephropathy reduces GFR over time, lisinopril (or another ACE inhibitor) is often used specifically to slow that progression, and diabetic peripheral neuropathy is one of the more common reasons gabapentin gets prescribed in the first place. These three facts overlap often enough that gabapentin dose reductions should be anticipated as CKD advances in this population, even when the lisinopril dose itself stays the same.

Older adults. Kidney function tends to decline gradually with age, and older adults are often more sensitive to gabapentin's CNS effects at a given blood level. Geriatric prescribing guidance (the American Geriatrics Society Beers Criteria) has flagged gabapentin as a medication warranting caution in older adults because of fall and cognitive-impairment risk; this concern compounds with lisinopril's own orthostatic-hypotension potential. A conservative starting gabapentin dose with slow titration is a reasonable approach in this group, decided individually with the prescriber rather than by a fixed rule.

Patients on opioids. Lisinopril, gabapentin, and an opioid together shift the respiratory-depression risk from theoretical to something requiring active monitoring, consistent with prior regulatory warnings on gabapentinoids. This three-drug combination warrants the closest attention of any scenario discussed here.

What is established, what is plausible, and what is not established

Established: Lisinopril and gabapentin have no direct pharmacokinetic interaction because neither involves CYP450 metabolism or P-glycoprotein transport. Both drugs are cleared primarily by the kidney. Reduced kidney function requires dose adjustment of both drugs individually, per their respective product labeling. [2] Combining gabapentinoids with opioids or other CNS depressants carries a regulatory-flagged respiratory depression risk that is amplified by reduced renal clearance.

Plausible but not quantified in a verified interaction-specific study: The exact magnitude by which lisinopril-associated GFR reduction raises gabapentin blood levels in a typical patient has not been isolated in a dedicated interaction trial in the sources reviewed for this article. The mechanism is coherent based on each drug's independent renal pharmacology, but a specific numeric estimate for "how much gabapentin levels rise when lisinopril is added" would need a study designed to answer that exact question.

Not established here: Any precise odds ratio for gabapentin-associated orthostatic hypotension, and any verbatim guideline quotation attributed to KDIGO or AHA documents, could not be confirmed against a verified source during this review and have been removed rather than presented as fact. A reader or clinician who needs these figures should pull the current primary guideline or study directly.

Is it safe to take lisinopril and gabapentin together?

For most patients with normal or near-normal kidney function, yes, the combination is used routinely without a mandatory dose adjustment based on the interaction alone. The practical steps that keep it safe:

1. Check eGFR before starting either drug in a patient already on the other, and again after any dose change.
2. Review the gabapentin dose against the current FDA label whenever eGFR drops meaningfully, rather than waiting for symptoms.
3. Counsel on hydration, avoiding routine NSAID use (NSAIDs can reduce kidney function and blunt lisinopril's effect), and reporting new sedation, unsteadiness, or falls promptly.
4. Reassess more frequently in older adults, patients with CKD, patients with diabetes, and anyone recently started on a diuretic.
5. Treat the three-drug combination of lisinopril, gabapentin, and an opioid as requiring the closest monitoring of all the scenarios above.

None of this requires avoiding the combination. It requires tracking kidney function as a shared variable that connects two otherwise unrelated drugs.

When to seek urgent care

New confusion, difficulty staying awake, slowed or labored breathing, or a fall with possible injury in a patient taking gabapentin (with or without lisinopril) warrants urgent medical evaluation rather than waiting for a routine follow-up appointment, particularly if an opioid or other sedating medication is also involved.